Literature DB >> 22824214

Treatment of craniopharyngioma in adults: systematic analysis of a 25-year experience.

Raul Lopez-Serna1, Juan Luis Gómez-Amador, Juan Barges-Coll, Edgar Nathal-Vera, Rogelio Revuelta-Gutiérrez, Mario Alonso-Vanegas, Miguel Ramos-Peek, Lesly Portocarrero-Ortiz.   

Abstract

BACKGROUND AND AIMS: Craniopharyngioma is a rare and mostly benign epithelial tumor of the central nervous system, mostly affecting children. Considering that most of the published series of craniopharyngioma are based on pediatric populations, studies in adults gain importance based mainly on the reduced number of cases and the possible differences emerging from a mostly different histological type. We undertook this study to establish the pattern of presentation, morphological features and specific characteristics of craniopharyngioma in an adult Mexican population, as well as discussing the long-term outcome and how it may be influenced by surgical, anatomic and clinical factors.
METHODS: A total of 153 adult patients (16 years or older) underwent transcranial and transsphenoidal surgery between January 1985 and December 2009, all with histological confirmation of craniopharyngioma. Hypothalamic involvement, surgical complications, rate of tumor resection and endocrinological outcome were evaluated.
RESULTS: Seventy nine males (51.6%) and 74 females (48.4%) were included. Mean age at diagnosis was 32.4 years (range: 16-77 years). Mean initial tumor volume was 28.44 mL (range: 0.18-100.44 mL). Partial or complete hypothalamic involvement (Samii Grades III, IV and V) was found in 90.2%. The overall rate of new endocrinopathies was 37.25% after surgery (95% CI = 33.9-41.2).
CONCLUSIONS: Gross total removal of craniopharyngiomas with large hypothalamic involvement was related to poor neuroendocrine outcome in adults. Partial removal should be indicated, associated with adjuvant therapy, in order to improve postoperative neuroendocrine status.
Copyright © 2012 IMSS. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22824214     DOI: 10.1016/j.arcmed.2012.06.009

Source DB:  PubMed          Journal:  Arch Med Res        ISSN: 0188-4409            Impact factor:   2.235


  7 in total

1.  CRANIOPHARYNGIOMA - CLINICAL AND THERAPEUTIC OUTCOME DATA IN A MIXED COHORT OF ADULT AND PAEDIATRIC CASES.

Authors:  C Capatina; M Vintila; I Gherlan; A Dumitraşcu; A Caragheorgheopol; C Procopiuc; V Ciubotaru; C Poiana
Journal:  Acta Endocrinol (Buchar)       Date:  2018 Oct-Dec       Impact factor: 0.877

2.  Primary ectopic frontotemporal craniopharyngioma.

Authors:  Luis Alberto Ortega-Porcayo; Juan Antonio Ponce-Gómez; Mauricio Martínez-Moreno; Lesly Portocarrero-Ortíz; Martha Lilia Tena-Suck; Juan Luis Gómez-Amador
Journal:  Int J Surg Case Rep       Date:  2015-01-08

3.  Is the Complete Resection of Craniopharyngiomas in Adults Feasible Considering Both the Oncologic and Functional Outcomes?

Authors:  Eun Jung Lee; Young Hyun Cho; Seok Ho Hong; Jeong Hoon Kim; Chang Jin Kim
Journal:  J Korean Neurosurg Soc       Date:  2015-11-30

Review 4.  Endocrine Disorder in Patients With Craniopharyngioma.

Authors:  Zihao Zhou; Sheng Zhang; Fangqi Hu
Journal:  Front Neurol       Date:  2021-12-02       Impact factor: 4.003

5.  Endoscopic Endonasal Transsphenoidal Surgery for Recurrent Craniopharyngiomas.

Authors:  Zhenguang Feng; Chuzhong Li; Lei Cao; Ning Qiao; Wentao Wu; Jiwei Bai; Peng Zhao; Songbai Gui
Journal:  Front Neurol       Date:  2022-04-11       Impact factor: 4.003

Review 6.  Association of histological subtype with risk of recurrence in craniopharyngioma patients: a systematic review and meta-analysis.

Authors:  Jie Wu; Xiao Wu; You Qing Yang; Han Ding; Le Yang; You Yuan Bao; Lin Zhou; Chen Xing Yang; Tao Hong
Journal:  Neurosurg Rev       Date:  2021-06-22       Impact factor: 2.800

Review 7.  Typical Pediatric Brain Tumors Occurring in Adults-Differences in Management and Outcome.

Authors:  Ladina Greuter; Raphael Guzman; Jehuda Soleman
Journal:  Biomedicines       Date:  2021-03-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.